- 专利标题: p63 inactivation for the treatment of heart failure
-
申请号: US17813493申请日: 2022-07-19
-
公开(公告)号: US12031135B2公开(公告)日: 2024-07-09
- 发明人: Vivekkumar B. Patel , Hongran Wang , Vivek P. Singh , Erin Lynn Reineke , Megumi Mathison , Austin J. Cooney , Todd Rosengart
- 申请人: Baylor College of Medicine
- 申请人地址: US TX Houston
- 专利权人: Baylor College of Medicine
- 当前专利权人: Baylor College of Medicine
- 当前专利权人地址: US TX Houston
- 代理机构: Norton Rose Fulbright US LLP
- 主分类号: C12N15/86
- IPC分类号: C12N15/86 ; A61K9/00 ; A61K31/47 ; A61K31/713 ; A61K38/17 ; A61K48/00 ; C07K14/47 ; C07K14/82 ; C12N5/077 ; C12N15/113
摘要:
Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
公开/授权文献
- US20220348921A1 p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE 公开/授权日:2022-11-03
信息查询
IPC分类: